About "PK repeats" [Software]

posted by Helmut Homepage – Vienna, Austria, 2010-10-21 19:01 (5297 d 13:59 ago) – Posting: # 6072
Views: 15,888

Dear Ohlbe!

❝ ❝ Following the presentation, a comment was brought forth stating that regulatory agencies recommend against performing PK repeats


❝ Unfortunately. But remember the discussions at the EBF/EUFEPS meeting in Brussels in April: on the European side there is still some hope that the ban will be restricted to BE trials only, not to other PK trials. And there is still a possibility in the draft for repeats for lab investigations. So we are not completely loosing our time.


Yes, I remember. ;-)
But I must confess that I don't see the rationale behind 'a ban on BE studies'. Much more is know about the PK of the drug at that stage as compared to FIM or PK-studies of the innovator...

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
26 visitors (0 registered, 26 guests [including 4 identified bots]).
Forum time: 09:01 CEST (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5